Overview of the drug development pipeline for basal cell carcinoma
It has been observed that basal cell carcinoma is a type of skin cancer and is characterized by uncontrolled and abnormal growth or lesions on the skin’s basal cells. It generally does not spread, and if it does, then it is extremely harmful and needs to be treated promptly. It mainly occurs on those body parts that are exposed to the sun, such as face, ears, neck, scalp, shoulders, and back. Sometimes an accidental contact with arsenic complications from burns, or exposure to radiation may impact the sores. The common symptoms of basal cell carcinoma are dome-shaped skin growth or open sores with blood vessels in it and raided red patches that may contain abnormal blood vessels. Monotherapy is emerging as the most effective approach for the treatment of basal cell carcinoma.
According to this pipeline analysis report, all the drug molecules in the pipeline are being developed for basal cell carcinoma. Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.
Want a bigger picture? Get a free sample of this report now!
Companies covered
This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of basal cell carcinoma. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug molecules discontinued by companies.
Some of the companies covered in this pipeline analysis report are –
- Adgero Biopharmaceuticals Holdings
- Ascend Biopharmacueticals
- Biofrontera
Therapeutic assessment of the drug development pipeline for basal cell carcinoma by route of administration
- Topical
- Oral
- Intravenous
- Intratumoral
- Oral/topical
- Unknown
The topical route of administration (ROA) involves the application of the drug directly onto a specific surface area of the body and in the oral technique, the molecules are directly delivered to the mouth cavity, which will have a more direct effect on the target cells.
Therapeutic assessment of the drug development pipeline for basal cell carcinoma by therapy
- Monotherapy
- Combination therapy
- Monotherapy/combination therapy
According to this pipeline analysis report, most of the molecules that are currently in the drug pipeline for basal cell carcinoma are being developed as monotherapy drugs and most of these molecules are in the pre-clinical stage of development.
Key questions answered in the report include
- What are the gene therapy molecules in the various development stages for basal cell carcinoma?
- What are the companies that are currently involved in the development of drug molecules for basal cell carcinoma?
- Insight into discontinued/inactive molecules with appropriate reasoning?
- What are the major regulatory authorities approving drugs in various regions?
- Detailed profiling of each active molecule
Technavio also offers customization on reports based on specific client requirement.
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: INTRODUCTION
PART 05: MAJOR REGULATORY AUTHORITIES
PART 06: PIPELINE LANDSCAPE
PART 07: COMPARATIVE ANALYSIS
- Discovery stage molecules
- Pre-clinical stage molecules
- Inactive and discontinued molecules
PART 08: INDICATION ANALYSIS
PART 09: THERAPEUTIC ASSESSMENT (THERAPY BASED)
PART 10: THERAPEUTIC ASSESSMENT (ROA BASED)
PART 11: THERAPEUTIC ASSESSMENT BY TARGET
PART 12: KEY COMPANIES
- Active companies: Category and parameters
PART 13: APPENDIX